Patients with mixed astigmatism achieve good results after refractive treatment

Houston—The CustomVue refractive treatment (VISX/AMO) for patients with mixed astigmatism demonstrated good results at 6 months, according to Douglas D. Koch, MD.

Related Videos
Related Content

Teprotumumab: First FDA-approved treatment for TED

June 1st 2023

Podcast: Wet AMD and the treatment burden on patients

May 3rd 2023

Prevent Blindness to mark ‘Prevent Blindness Day’ on June 1

May 31st 2023

Podcast: AI/MR in ophthalmology: The future is now

April 7th 2023

Preservative-free latanoprost vs BAK-preserved latanoprost

May 31st 2023

Optos unveils ultra-widefield color image modality, offering increased retinal visualization to ophthalmologists

May 30th 2023

Teprotumumab: First FDA-approved treatment for TED

June 1st 2023

Podcast: Wet AMD and the treatment burden on patients

May 3rd 2023

Prevent Blindness to mark ‘Prevent Blindness Day’ on June 1

May 31st 2023

Podcast: AI/MR in ophthalmology: The future is now

April 7th 2023

Preservative-free latanoprost vs BAK-preserved latanoprost

May 31st 2023

Optos unveils ultra-widefield color image modality, offering increased retinal visualization to ophthalmologists

May 30th 2023

Teprotumumab: First FDA-approved treatment for TED

June 1st 2023

Podcast: Wet AMD and the treatment burden on patients

May 3rd 2023

Prevent Blindness to mark ‘Prevent Blindness Day’ on June 1

May 31st 2023

Podcast: AI/MR in ophthalmology: The future is now

April 7th 2023

Preservative-free latanoprost vs BAK-preserved latanoprost

May 31st 2023

Optos unveils ultra-widefield color image modality, offering increased retinal visualization to ophthalmologists

May 30th 2023
© 2023 MJH Life Sciences

All rights reserved.